Copernicus Therapeutics Inc

Copernicus Therapeutics, Inc. (CTI) is a clinical stage, privately held company located in Cleveland, Ohio. The company employs 5 people and generates an estimated $2.5 million in annual revenue. CTI focuses on developing genomics medicines with the potential to offer functional cures for patients with genetic disorders. CTI's proprietary non-viral nucleic acid delivery platform enables the transport of large genetic payloads into cells. This platform utilizes a receptor-mediated mechanism to achieve robust gene transfer, minimizing the immune response often associated with traditional viral gene therapies like AAV. Complementing this technology is CTI's intellectual property in plasmid design, which ensures long-term and controlled gene expression. The company is currently developing programs targeting cystic fibrosis, eye disorders, and brain diseases. CTI has completed Phase I/II clinical trials for cystic fibrosis and is progressing with pre-clinical research for eye and brain treatments. For more information about Copernicus Therapeutics, Inc., please visit cgsys.com.